Coastal Financial에 대한 매도 수량은 투자자에게 Coastal Financial의 주식 하락에 베팅하는 정도를 알려줍니다. 매도 수량 데이터는 2주마다 업데이트됩니다.

Coastal Financial (NASDAQ:CCB) 주식, 공매도 수량 보고

COASTAL FINANCIAL CORP/WA

Coastal Finl

Coastal Financial Corp is a bank holding company. Through its subsidiaries, the company conducts its business in three reportable segments which include, Community Bank, CCBX, and Treasury and Administration. The Community Bank segment includes all community banking activities, with a primary focus on providing various banking products and services to consumers and small to medium-sized businesses. The CCBX segment provides Banking as a Service (BaaS) that allows its broker dealers and digital financial service partners to offer their customers banking services, and the Treasury and administration segment includes treasury management, overall administration, and all other aspects of the company. The maximum revenue of the company is generated from the CCBX segment.

Robinhood,,An,Online,Investing,Platform,,Mobile,App,Displayed,On,The

Equities

News

Markets

HOOD

로빈후드 마켓츠(NASDAQ:HOOD)는 보다 정교한 프라이빗 뱅킹 및 투자 솔루션을 찾는 개인 투자자를 유치하기 위해 설계된 통합 금융 서비스 제품군을 출시해 비즈니스 모델을 혁신하고 있다. 

로빈후드, 은행 업계로 확대...연 이자율 4% 및 현금 배송 서비스 제공

Coastal Financial Corporation - Common Stock

Coastal Financial Corp

CHINO COMML BANCORP (CA) by Chino Commercial Bancorp

Chino Commercial Bancorp

Capital City Bank Group Inc

CHINA CBM GROUP CO LTD by CHINA CBM GROUP CO LTD.

Penguin Solutions (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PENG#NASDAQ">PENG</a>) reported quarterly earnings of $0.52 per share which beat the analyst consensus estimate of $0.38 by 36.84 percent. This is a 92.59 percent increase over earnings of $0.27 per share from the same period last year. The company reported quarterly sales of $365.52 million which beat the analyst consensus estimate of $344.97 million by 5.96 percent. This is a 28.33 percent increase over sales of $284.82 million the same period last year.

Earnings

Earnings Beats

Penguin Solutions, Inc. - Ordinary Shares

PENG

Penguin Solutions Q2 2025 Adj EPS $0.52 Beats $0.38 Estimate, Sales $365.52M Beat $344.97M Estimate

Resources Connection (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RGP#NASDAQ">RGP</a>) reported quarterly losses of $(0.08) per share which beat the analyst consensus estimate of $(0.10) by 20 percent. This is a 147.06 percent decrease over earnings of $0.17 per share from the same period last year. The company reported quarterly sales of $129.40 million which missed the analyst consensus estimate of $130.00 million by 0.46 percent. This is a 14.48 percent decrease over sales of $151.31 million the same period last year.

Earnings Misses

Resources Connection Q3 2025 Adj EPS $(0.08) Beats $(0.10) Estimate, Sales $129.40M Miss $130.00M Estimate

Denali Therapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DNLI#NASDAQ">DNLI</a>) shares traded higher on Wednesday after the company initiated its biologics license application (BLA) for the accelerated approval of Tividenofusp Alfa for the treatment <a href="https://www.benzinga.com//node/44604609">of Hunter syndrome</a>.
What To Know: Denali announced that it expects the BLA application to be completed by mid-May. The company is preparing for a potential U.S. commercial launch in late 2025 or early 2026.
&#8220;We are grateful to the FDA for their ongoing support of our BLA filing and continued dedication to advance new medicines. This regulatory milestone brings us closer to our goal of delivering a new treatment option to the Hunter syndrome community as we continue to listen, learn, and seek their advice in bringing tividenofusp alfa to patients,&#8221; said Carole Ho, chief medical officer of Denali.
&#8220;Our progress has broader positive implications supporting the expansion of our Enzyme Transport Vehicle franchise of next-generation enzyme replacement therapies to treat the brain and body. In this context, we appreciate the ongoing and productive collaboration with CDER through the START program as we align on an accelerated development and approval path for DNL126 for the potential treatment of Sanfilippo syndrome.&#8221;
Denali Therapeutics is a biopharmaceutical company developing a portfolio of product candidates engineered to cross the blood-brain barrier for neurodegenerative diseases and lysosomal storage diseases.
See Also: <a href="https://www.benzinga.com/etfs/specialty-etfs/25/04/44613351/chipotles-stock-is-sizzling-bill-ackman-loves-it-and-these-etfs-do-too">Chipotle&#8217;s Stock Is Sizzling—Bill Ackman Loves It And These ETFs Do Too</a>
DNLI Price Action: Denali shares closed Wednesday up 11.8% at $13.74, according to data from <a href="https://www.benzinga.com/pro/">Benzinga Pro</a>.
Image via Shutterstock

Movers

DNLI

What Happened To Denali Therapeutics Stock Wednesday?

Management

DLTH

Duluth Holdings Appoints Stephanie Pugliese As President And CEO, Effective May 5, 2025

Macro Economic Events

Politics

Economics

General

President Trump Says Jobs And Factories Will Come Back

Equity Bancshares, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EQBK#NYSE">EQBK</a>) ("Equity" or the "Company"), the Wichita-based holding company of Equity Bank, announced today its entry into a definitive merger agreement with NBC Corp. of Oklahoma ("NBC"), the parent company of NBC Oklahoma, in Oklahoma City, Oklahoma. Equity will merge NBC into Equity, adding seven locations to Equity Bank's current network.
"We are excited to expand our presence in Oklahoma through this strategic merger," said Equity Bancshares, Inc. Chairman &amp; CEO Brad Elliott. "This partnership builds on our shared commitment to the communities we serve and enhances our ability to provide exceptional financial services to the Oklahoma City metro and Altus, Alva, Enid and Kingfisher communities, a southern expansion we are excited to take on with the NBC team. The NBC franchise is similar to Equity from a customer and deposit mix standpoint. By combining our resources, expertise, and shared values, we look forward to driving growth and delivering even greater value to our customers and stockholders."
"We are pleased to join forces with Equity in this exciting new chapter," said NBC Chairman of the Board Ken Fergeson. "In partnering with Equity Bank, we will continue to deliver the exceptional service and innovative financial solutions our clients expect, while our customers and teams benefit from expanded resources and opportunities for growth. Like NBC, Brad and the Equity team value both metro and community markets, and we are thrilled to enhance our banking services to each."

Contracts

EQBK

Equity Bancshares Enters Partnership With NBC Oklahoma, Adds to Oklahoma Franchis

Lucid intends to use the net proceeds of the offering, after deducting the initial purchasers' discounts and commissions and its estimated offering expenses, to (i) repurchase a portion of its outstanding 1.25% Convertible Senior Notes due 2026 and (ii) pay the cost of the capped call transactions.
 &nbsp;

Offerings

LCID

Lucid Group Intends To Offer $1B Of Convertible Senior Notes Due 2030 In Private Offering

President Trump Says In A Few Moments I Will Sign Executive Order For Reciprocal Tariffs

WIIM

RH shares are trading lower after the company reported Q4 financial results and missed its adjusted EPS and revenue estimates.

This is after taking into consideration the timing of the distribution agreement expiration at the close of Q3 2025 and wind down activities over the six months thereafter, during which the Company will continue selling remaining inventory.

Guidance

NPCE

NeuroPace Maintains 2025 Revenue Guidance And Long-Range Plan Expectations Of 20%+ CAGR And Ability To Achieve Cash Flow Breakeven By End Of 2027

RH Sees FY25 Revenue Growth 10%-13%

EL MONTE, Calif., April 02, 2025 (GLOBE NEWSWIRE) -- GigaCloud Technology Inc (NASDAQ:<a href="https://www.benzinga.com/stock/GCT#NASDAQ">GCT</a>) ("GigaCloud" or the "Company"), a pioneer of global end-to-end B2B ecommerce technology solutions for large parcel merchandise, today announced that on March 28, 2025, its Board of Directors approved an additional $16 million to its Class A ordinary share repurchase program, bringing the total authorization to $62 million from its previously authorized $46 million. The program runs through August 28, 2025.
Under the share repurchase program, the Company may purchase its ordinary shares through various means, including open market transactions, privately negotiated transactions, block trades, any combination thereof or other legally permissible means. The Company may effect repurchase transactions in compliance with Rule 10b5-1 and Rule 10b-18 of the Securities Exchange Act of 1934, as amended. The number of shares repurchased and the timing of repurchases will depend on a number of factors, including, but not limited to, share price and trading volume, and general market conditions, along with the Company's working capital requirements, general business conditions and other factors. The Company's board of directors will review the share repurchase program periodically, and may modify, suspend or terminate the share repurchase program at any time. The Company plans to fund repurchases from its existing cash balance.

Buybacks

GigaCloud Technology Increases It's Share Repurchase Program By $16M

RH Sees Q1 Revenue Growth 12.5%-13.5%

RH (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RH#NYSE">RH</a>) reported quarterly earnings of $1.58 per share which missed the analyst consensus estimate of $1.92 by 17.71 percent. This is a 119.44 percent increase over earnings of $0.72 per share from the same period last year. The company reported quarterly sales of $812.406 million which missed the analyst consensus estimate of $829.563 million by 2.07 percent. This is a 10.04 percent increase over sales of $738.260 million the same period last year.

RH Q4 2024 Adj. EPS $1.58 Misses $1.92 Estimate, Sales $812.406M Miss $829.563M Estimate

NeuroPace Terminates Distribution Relationship For SEEG Products, To Begin Winding Down The Relationship In Q4 Of 2025 And Continuing Through Q1 Of 2026

On March 14, 2025, Aristocrat filed a second amended complaint with the District Court of Nevada, adding a trade secret misappropriation claim against Jewel of the Dragon. The initial claims concerning Jewel of the Dragon did not include a claim for trade secret misappropriation. We intend to respond to the second amended complaint by April 11, 2025.
In the latest complaint, Aristocrat has also raised new issues, which we intend to vigorously defend against.

Legal

Light & Wonder Provides Update On Ligitation With Aristocrat

Econ #s

White House Close To Approving Sale Of TikTok US Unit To New, Existing Investors-Financial Times

<a href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.fluor.com%2F&amp;esheet=54232853&amp;newsitemid=20250402439876&amp;lan=en-US&amp;anchor=Fluor+Corporation&amp;index=1&amp;md5=c2a26ed6bea1455907b7ac1f37aceeee">Fluor Corporation</a> (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FLR#NYSE">FLR</a>) announced today that it has received a letter of intent from one of the world's leading pharmaceutical makers to provide engineering, procurement and construction management (EPCM) services for its Lebanon, Indiana, mega-project. Fluor will recognize the multi-billion-dollar reimbursable contract as a new award in the first quarter of 2025.
This investment is in addition to its first multi-billion-dollar project that was awarded to Fluor in 2023.
The facility will manufacture groundbreaking peptide-based drugs for Type 2 diabetes and weight control and represents the largest investment in an active pharmaceutical ingredient facility in U.S. history.
"This monumental project stands as one of the largest life science endeavors ever undertaken in a single initiative and demonstrates Fluor's EPCM leadership position in the sector," said Richard Meserole, President of Fluor's Advanced Technologies &amp; Life Sciences business. "The products this facility manufactures have the ability to enhance the overall wellbeing of its users globally. Fluor is honored to be delivering it."

Fluor Announces It Will Provide Engineering, Procurement And, Construction Management Services For A Second Multi-Billion-Dollar Pharmaceutical Facility In Indiana

Data demonstrate EXACT has potential to overcome limitations of conventional gene therapy for dosage-sensitive disorders
Findings published in Science Translational Medicine

Biotech

NGNE

Neurogene Announces Peer-Reviewed Publication Demonstrating Gene Therapy Candidate NGN-401 With EXACT Technology Regulates Transgene Expression On Preclinical Models Of Rett Syndrome

Cenovus Energy (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CVE#NYSE">CVE</a>) has outperformed the market over the past 5 years by 22.21% on an annualized basis producing an average annual return of 38.54%. Currently, Cenovus Energy has a market capitalization of $25.23 billion. 
Buying $100 In CVE: If an investor had bought $100 of CVE stock 5 years ago, it would be worth $523.69 today based on a price of $13.85 for CVE at the time of writing.
<h3>Cenovus Energy's Performance Over Last 5 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1743624127_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Comments

Coastal Financial

매도 수량

Coastal Financial (NASDAQ:CCB) 주식, 공매도 수량 보고

사람들이 또한 지켜본다

뉴스

파트너 / 기고자

벤징가 글로벌